3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Advanced Solid Tumours
5
Squamous Cell Carcinoma of Head and Neck
3
Solid Tumors
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Leukemia, Myeloid, Acute
2
Glioblastoma
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Muscle Invasive Bladder Cancer
1
Meningeal Carcinomatosis
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Laryngeal Neoplasms
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Carcinoma, Endometrioid
1
Brain Neoplasms
1
Blast Crisis
1
Astrocytoma
1
Advanced Solid Tumors
1
Adenocarcinoma Of Esophagus
1
Interventions
vistusertib
1
tislelizumab
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
Rutin
1
Gemcitabine
1
Cisplatin
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Muscle Invasive Bladder Cancer
×
adavosertib
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled